Search company, investor...


Founded Year



Loan | Alive

Total Raised


Last Raised

$3M | 4 yrs ago

About AngioChem

AngioChem is a clinical-stage biotechnology discovering and developing drugs that are capable of crossing the blood-brain barrier to treat brain diseases. The company's EPiC platform aims to solve the key problem for crossing the blood-brain barrier by developing drugs that use a receptor-based approach.

Headquarters Location

201 President-Kennedy Ave. Suite PK-R220

Montreal, Quebec, H2X 3Y7,



Missing: AngioChem's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: AngioChem's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing AngioChem

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AngioChem is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

AngioChem Patents

AngioChem has filed 1 patent.

The 3 most popular patent topics include:

  • Cancer treatments
  • Clusters of differentiation
  • EC 6.3.2
patents chart

Application Date

Grant Date


Related Topics




Antineoplastic drugs, Experimental cancer drugs, Alkylating antineoplastic agents, Mitotic inhibitors, Cancer treatments


Application Date


Grant Date



Related Topics

Antineoplastic drugs, Experimental cancer drugs, Alkylating antineoplastic agents, Mitotic inhibitors, Cancer treatments



Latest AngioChem News

Nov 25, 2021, 23:00 ET Glioblastoma Multiforme Treatment Market to grow by USD 1.41 billion | Evolving Opportunities with Amgen ...

Nov 26, 2021

| Evolving Opportunities with Amgen Inc. & Amneal Pharmaceuticals Inc. | 17000+ Technavio Reports News provided by Share this article Share this article NEW YORK, Nov. 25, 2021 /PRNewswire/ -- Technavio's latest offering, the  Glioblastoma Multiforme Treatment Market report provides a detailed analysis of the competitive scenario and the market growth across various regions. The glioblastoma multiforme treatment market is expected to increase by USD 1.41 billion from 2021 to 2026 at a CAGR of 8.48%. 37% of the market's growth will originate from North America. The US and Canada are the key markets for glioblastoma multiforme treatment in the region. The favorable government initiatives will facilitate the glioblastoma multiforme treatment market growth in North America. Attractive Opportunities in Glioblastoma Multiforme Treatment Market by End-user and Geography - Forecast and Analysis 2022-2026 Market Dynamics Factors such as the increasing incidence of glioblastoma multiforme and the increasing geriatric population will drive the growth of the Glioblastoma Multiforme Treatment Market. However, adverse effects associated with treatments might hamper the market growth. Company Profiles The glioblastoma multiforme treatment market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market. The glioblastoma multiforme treatment market report provides complete insights on key vendors including Amgen Inc., Amneal Pharmaceuticals Inc., Angiochem Inc., Arbor Pharmaceuticals LLC, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., Pfizer Inc., Sumitomo Dainippon Pharma Co. Ltd., and Sun Pharmaceutical Industries Ltd. Few Companies with Key Offerings Amgen Inc.- The company offers an injection solution namely AMGEVITA for glioblastoma multiforme treatment. Amneal Pharmaceuticals Inc. - The company offers injection solutions namely Acyclovir for glioblastoma multiforme treatment. Angiochem Inc. - The company offers Antibody-drug conjugates (ADCs) for glioblastoma multiforme treatment. Competitive Analysis The report includes the competitive analysis, a proprietary tool to analyze and evaluate the position of companies based on their industry position score and market performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc. Market Segmentation By End-user, the market is classified into Hospitals, Clinics, and Ambulatory Surgical Centers. The glioblastoma multiforme treatment market share growth by the hospital segment has been significant. By Geography, the market is classified as North America, Europe, Asia, and ROW. North America will have the largest share of the market. Related Reports- Liposomal Products Market  -The liposomal products market share should rise by USD 2.21 billion from 2021 to 2026 at a CAGR of 7.81%. Download a free sample now! GERD Market -The GERD market share should rise by USD 793.85 million between 2021 and 2025 at a CAGR of 3.01%. Download a free sample now! Glioblastoma Multiforme Treatment Market Scope Report Coverage Companies profiled Amgen Inc., Amneal Pharmaceuticals Inc.,  Angiochem Inc., Arbor Pharmaceuticals LLC, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., Pfizer Inc., Sumitomo Dainippon Pharma Co. Ltd., and Sun Pharmaceutical Industries Ltd. Market Dynamics Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period Customization purview If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact

AngioChem Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AngioChem Rank

AngioChem Frequently Asked Questions (FAQ)

  • When was AngioChem founded?

    AngioChem was founded in 2003.

  • Where is AngioChem's headquarters?

    AngioChem's headquarters is located at 201 President-Kennedy Ave., Montreal.

  • What is AngioChem's latest funding round?

    AngioChem's latest funding round is Loan.

  • How much did AngioChem raise?

    AngioChem raised a total of $14.77M.

  • Who are the investors of AngioChem?

    Investors of AngioChem include Government of Quebec, BDC Capital, VIMAC Ventures and BDC Healthcare Venture Fund.

  • Who are AngioChem's competitors?

    Competitors of AngioChem include Cerecin, Longevica, MaxCyte, Panacea Pharmaceuticals, Array Biopharma and 13 more.

Compare AngioChem to Competitors

Edunn Biotechnology

Edunn Biotechnology, Inc. is developing oligonucleotide drugs to treat central nervous system diseases. The company currently has two drugs in development. Edunn's OL-1 drug is designed to cure Alzheimer's disease and to treat Down syndrome. Per the company, it is highly selective and has shown significant activity and safety in multiple preclinical models. The company's OL-202 would be used to treat stroke and traumatic brain injury.

Cerecin Logo

Cerecin is a biopharmaceutical company with a drug for Alzheimer's in late-stage clinical testing. Cerecin's pipeline consists of therapeutic drugs and medical foods for neurodegenerative diseases such as Alzheimer's, Parkinson's, and Age-Associated Memory Impairment. The company was founded in 2001 and is based in Singapore.

Longevica Logo

Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.


Antoxis is a Scotland (Aberdeen) based biotechnology company focused on therapeutic antioxidants. The company's products aim to target and destroy damaging free radicals that are generated in excessive amounts in a number of clinical conditions. The company's initial focus is neurodegeneration, in particular ischaemic stroke and Alzheimer's disease.

Topigen Pharmaceuticals

Topigen is a biopharmaceutical company developing several new classes of drugs for respiratory disorders based upon its platform technology using DNARNA chemistry. These drugs are focused on inhibiting multiple inflammatory pathways at the cellular site of inflammation using a single drug product. Per the company, this approach has shown promising preclinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma COPD and allergic rhinitis AR.


REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.